TY - JOUR TI - Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? AU - Bitting,Rhonda L. AU - Armstrong, Andrew J. AU - George,Daniel J. PY - 2011/10/20 AB - Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population. KW - DB - Libertas Academica DP - Libertas Academica LA - English SP - 325 EP - 332 JO - Clinical Medicine Insights: Oncology VL - 5 IS - 2880-CMO-Management-Options-in-Advanced-Prostate-Cancer:-What-is-the-Role-for-S.pdf SN - UR - www.la-press.com/management-options-in-advanced-prostate-cancer-what-is-the-role-for-si-article-a2880 L1 - www.la-press.com/redirect_file.php?fileId=3861&filename=2880-CMO-Management-Options-in-Advanced-Prostate-Cancer:-What-is-the-Role-for-S.pdf&fileType=pdf DO - 10.4137/CMO.S5977 ER -